BACKGROUND: Interleukin 6 (IL-6) is an inflammatory cytokine that has been associated with vascular disease and cognitive impairment, but few studies have examined these relationships in population-based studies that include Hispanic and Black people who often have a greater prevalence of vascular risk factors and are at an elevated risk of dementia than Whites. We examined relative elevations of plasma IL-6 concentrations in relation to cognitive decline in a stroke-free racially/ethnically diverse community-based sample from Northern Manhattan. METHODS: We used mixed effects models to measure the effect of IL-6 on change in performance on the modified Telephone Interview for Cognitive Status (TICS-m) measured annually in our cohort, adjusting for sociodemographic and vascular risk factors. RESULTS: There were 1,224 participants with IL-6 levels (median 1.5 pg/ml, interquartile range 0.83-2.57 pg/ml) and TICS-m data available (mean = 31.6 points, SD 6.5). The mean age was 71 (SD 9.3; 64% women, 59% Hispanic, 19% Black, 19% White) with 3,406 person-years and a median 3.0 years of follow-up (interquartile range 1.1-4.0 years). Participants with IL-6 levels above the median showed greater cognitive decline on the TICS-m compared to those with levels below the median, adjusting for sociodemographic and vascular factors (β = -0.17 points/year, p = 0.02). Decline on the TICS-m among participants with IL-6 above the median differed by age (p for interaction <0.001). There was no interaction by race/ethnicity, vascular risk factors, C-reactive protein, apolipoprotein ε4 allele status, or the metabolic syndrome among nondiabetics. CONCLUSIONS: IL-6 associated with cognitive decline among older participants in this racially/ethnically diverse sample independent of other vascular risk factors and C-reactive protein.
BACKGROUND:Interleukin 6 (IL-6) is an inflammatory cytokine that has been associated with vascular disease and cognitive impairment, but few studies have examined these relationships in population-based studies that include Hispanic and Black people who often have a greater prevalence of vascular risk factors and are at an elevated risk of dementia than Whites. We examined relative elevations of plasma IL-6 concentrations in relation to cognitive decline in a stroke-free racially/ethnically diverse community-based sample from Northern Manhattan. METHODS: We used mixed effects models to measure the effect of IL-6 on change in performance on the modified Telephone Interview for Cognitive Status (TICS-m) measured annually in our cohort, adjusting for sociodemographic and vascular risk factors. RESULTS: There were 1,224 participants with IL-6 levels (median 1.5 pg/ml, interquartile range 0.83-2.57 pg/ml) and TICS-m data available (mean = 31.6 points, SD 6.5). The mean age was 71 (SD 9.3; 64% women, 59% Hispanic, 19% Black, 19% White) with 3,406 person-years and a median 3.0 years of follow-up (interquartile range 1.1-4.0 years). Participants with IL-6 levels above the median showed greater cognitive decline on the TICS-m compared to those with levels below the median, adjusting for sociodemographic and vascular factors (β = -0.17 points/year, p = 0.02). Decline on the TICS-m among participants with IL-6 above the median differed by age (p for interaction <0.001). There was no interaction by race/ethnicity, vascular risk factors, C-reactive protein, apolipoprotein ε4 allele status, or the metabolic syndrome among nondiabetics. CONCLUSIONS:IL-6 associated with cognitive decline among older participants in this racially/ethnically diverse sample independent of other vascular risk factors and C-reactive protein.
Authors: Clinton B Wright; Mitchell S V Elkind; Tatjana Rundek; Bernadette Boden-Albala; Myunghee C Paik; Ralph L Sacco Journal: Stroke Date: 2006-04-06 Impact factor: 7.914
Authors: K Yaffe; K Lindquist; B W Penninx; E M Simonsick; M Pahor; S Kritchevsky; L Launer; L Kuller; S Rubin; T Harris Journal: Neurology Date: 2003-07-08 Impact factor: 9.910
Authors: Christopher C Patterson; Anne E Smith; John W G Yarnell; Ann Rumley; Yoav Ben-Shlomo; Gordon D O Lowe Journal: Atherosclerosis Date: 2009-09-27 Impact factor: 5.162
Authors: Snorri B Rafnsson; Ian J Deary; Felicity B Smith; Martha C Whiteman; Ann Rumley; Gordon D O Lowe; F Gerald R Fowkes Journal: J Am Geriatr Soc Date: 2007-05 Impact factor: 5.562
Authors: Vesna Jordanova; Robert Stewart; Emma Davies; Roy Sherwood; Martin Prince Journal: Int J Geriatr Psychiatry Date: 2007-10 Impact factor: 3.485
Authors: Andrea L Metti; Howard Aizenstein; Kristine Yaffe; Robert M Boudreau; Anne Newman; Lenore Launer; Peter J Gianaros; Oscar L Lopez; Judith Saxton; Diane G Ives; Stephen Kritchevsky; Abbe N Vallejo; Caterina Rosano Journal: Neurobiol Aging Date: 2015-07-28 Impact factor: 4.673
Authors: A Vilar-Bergua; I Riba-Llena; C Nafría; A Bustamante; V Llombart; P Delgado; J Montaner Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Mandip S Dhamoon; Yeseon Park Moon; Myunghee C Paik; Ralph L Sacco; Mitchell S V Elkind Journal: Ann Epidemiol Date: 2014-01-03 Impact factor: 3.797
Authors: Leah H Rubin; Lorie Benning; Sheila M Keating; Philip J Norris; Jane Burke-Miller; Antonia Savarese; Krithika N Kumanan; Saria Awadalla; Gayle Springer; Kathyrn Anastos; Mary Young; Joel Milam; Victor G Valcour; Kathleen M Weber; Pauline M Maki Journal: J Neurovirol Date: 2017-10-23 Impact factor: 2.643
Authors: Mary C Davis; Kathryn Lemery-Chalfant; Ellen WanHeung Yeung; Linda J Luecken; Alex J Zautra; Michael R Irwin Journal: Ann Behav Med Date: 2019-01-01
Authors: Alexandra M V Wennberg; Clinton E Hagen; Mary M Machulda; David S Knopman; Ronald C Petersen; Michelle M Mielke Journal: J Gerontol A Biol Sci Med Sci Date: 2019-07-12 Impact factor: 6.053